Header Logo

Connection

Sudhir Agrawal to Mice, Inbred BALB C

This is a "connection" page, showing publications Sudhir Agrawal has written about Mice, Inbred BALB C.
Connection Strength

0.813
  1. Putta MR, Zhu F, Li Y, Bhagat L, Cong Y, Kandimalla ER, Agrawal S. Novel oligodeoxynucleotide agonists of TLR9 containing N3-Me-dC or N1-Me-dG modifications. Nucleic Acids Res. 2006; 34(11):3231-8.
    View in: PubMed
    Score: 0.058
  2. Li Y, Kandimalla ER, Yu D, Agrawal S. Oligodeoxynucleotides containing synthetic immunostimulatory motifs augment potent Th1 immune responses to HBsAg in mice. Int Immunopharmacol. 2005 Jun; 5(6):981-91.
    View in: PubMed
    Score: 0.054
  3. Wang D, Kandimalla ER, Yu D, Tang JX, Agrawal S. Oral administration of second-generation immunomodulatory oligonucleotides induces mucosal Th1 immune responses and adjuvant activity. Vaccine. 2005 Apr 08; 23(20):2614-22.
    View in: PubMed
    Score: 0.053
  4. Zhu FG, Kandimalla ER, Yu D, Tang JX, Agrawal S. Modulation of ovalbumin-induced Th2 responses by second-generation immunomodulatory oligonucleotides in mice. Int Immunopharmacol. 2004 Jul; 4(7):851-62.
    View in: PubMed
    Score: 0.050
  5. Wang D, Li Y, Yu D, Song SS, Kandimalla ER, Agrawal S. Immunopharmacological and antitumor effects of second-generation immunomodulatory oligonucleotides containing synthetic CpR motifs. Int J Oncol. 2004 Apr; 24(4):901-8.
    View in: PubMed
    Score: 0.050
  6. Agrawal DK, Edwan J, Kandimalla ER, Yu D, Bhagat L, Wang D, Agrawal S. Novel immunomodulatory oligonucleotides prevent development of allergic airway inflammation and airway hyperresponsiveness in asthma. Int Immunopharmacol. 2004 Jan; 4(1):127-38.
    View in: PubMed
    Score: 0.049
  7. Kandimalla ER, Bhagat L, Zhu FG, Yu D, Cong YP, Wang D, Tang JX, Tang JY, Knetter CF, Lien E, Agrawal S. A dinucleotide motif in oligonucleotides shows potent immunomodulatory activity and overrides species-specific recognition observed with CpG motif. Proc Natl Acad Sci U S A. 2003 Nov 25; 100(24):14303-8.
    View in: PubMed
    Score: 0.048
  8. Kandimalla ER, Bhagat L, Cong YP, Pandey RK, Yu D, Zhao Q, Agrawal S. Secondary structures in CpG oligonucleotides affect immunostimulatory activity. Biochem Biophys Res Commun. 2003 Jul 11; 306(4):948-53.
    View in: PubMed
    Score: 0.047
  9. Kandimalla ER, Bhagat L, Wang D, Yu D, Zhu FG, Tang J, Wang H, Huang P, Zhang R, Agrawal S. Divergent synthetic nucleotide motif recognition pattern: design and development of potent immunomodulatory oligodeoxyribonucleotide agents with distinct cytokine induction profiles. Nucleic Acids Res. 2003 May 01; 31(9):2393-400.
    View in: PubMed
    Score: 0.046
  10. Yu D, Kandimalla ER, Zhao Q, Bhagat L, Cong Y, Agrawal S. Requirement of nucleobase proximal to CpG dinucleotide for immunostimulatory activity of synthetic CpG DNA. Bioorg Med Chem. 2003 Feb 06; 11(3):459-64.
    View in: PubMed
    Score: 0.046
  11. Yu D, Kandimalla ER, Bhagat L, Tang JY, Cong Y, Tang J, Agrawal S. 'Immunomers'--novel 3'-3'-linked CpG oligodeoxyribonucleotides as potent immunomodulatory agents. Nucleic Acids Res. 2002 Oct 15; 30(20):4460-9.
    View in: PubMed
    Score: 0.045
  12. Yu D, Kandimalla ER, Cong Y, Tang J, Tang JY, Zhao Q, Agrawal S. Design, synthesis, and immunostimulatory properties of CpG DNAs containing alkyl-linker substitutions: role of nucleosides in the flanking sequences. J Med Chem. 2002 Sep 26; 45(20):4540-8.
    View in: PubMed
    Score: 0.045
  13. Yu D, Zhu FG, Bhagat L, Wang H, Kandimalla ER, Zhang R, Agrawal S. Potent CpG oligonucleotides containing phosphodiester linkages: in vitro and in vivo immunostimulatory properties. Biochem Biophys Res Commun. 2002 Sep 13; 297(1):83-90.
    View in: PubMed
    Score: 0.044
  14. Kandimalla ER, Bhagat L, Yu D, Cong Y, Tang J, Agrawal S. Conjugation of ligands at the 5'-end of CpG DNA affects immunostimulatory activity. Bioconjug Chem. 2002 Sep-Oct; 13(5):966-74.
    View in: PubMed
    Score: 0.044
  15. Yu D, Kandimalla ER, Zhao Q, Cong Y, Agrawal S. Immunostimulatory properties of phosphorothioate CpG DNA containing both 3'-5'- and 2'-5'-internucleotide linkages. Nucleic Acids Res. 2002 Apr 01; 30(7):1613-9.
    View in: PubMed
    Score: 0.043
  16. Saha S, Bhanja P, Liu L, Alfieri AA, Yu D, Kandimalla ER, Agrawal S, Guha C. TLR9 agonist protects mice from radiation-induced gastrointestinal syndrome. PLoS One. 2012; 7(1):e29357.
    View in: PubMed
    Score: 0.021
  17. Conforti A, Cipriani B, Peruzzi D, Dharmapuri S, Kandimalla ER, Agrawal S, Mori F, Ciliberto G, La Monica N, Aurisicchio L. A TLR9 agonist enhances therapeutic effects of telomerase genetic vaccine. Vaccine. 2010 Apr 30; 28(20):3522-30.
    View in: PubMed
    Score: 0.019
  18. Damiano V, Garofalo S, Rosa R, Bianco R, Caputo R, Gelardi T, Merola G, Racioppi L, Garbi C, Kandimalla ER, Agrawal S, Tortora G. A novel toll-like receptor 9 agonist cooperates with trastuzumab in trastuzumab-resistant breast tumors through multiple mechanisms of action. Clin Cancer Res. 2009 Nov 15; 15(22):6921-30.
    View in: PubMed
    Score: 0.018
  19. Aurisicchio L, Peruzzi D, Conforti A, Dharmapuri S, Biondo A, Giampaoli S, Fridman A, Bagchi A, Winkelmann CT, Gibson R, Kandimalla ER, Agrawal S, Ciliberto G, La Monica N. Treatment of mammary carcinomas in HER-2 transgenic mice through combination of genetic vaccine and an agonist of Toll-like receptor 9. Clin Cancer Res. 2009 Mar 01; 15(5):1575-84.
    View in: PubMed
    Score: 0.017
  20. Damiano V, Caputo R, Garofalo S, Bianco R, Rosa R, Merola G, Gelardi T, Racioppi L, Fontanini G, De Placido S, Kandimalla ER, Agrawal S, Ciardiello F, Tortora G. TLR9 agonist acts by different mechanisms synergizing with bevacizumab in sensitive and cetuximab-resistant colon cancer xenografts. Proc Natl Acad Sci U S A. 2007 Jul 24; 104(30):12468-73.
    View in: PubMed
    Score: 0.016
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.